References
- Neumann PJ, Weinstein MC. Legislating against use of cost–effectiveness information. N. Engl. J. Med. 363(16), 1495–1497 (2010).
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies, Canada (3rd Edition). INAHTA, ON, USA (2006).
- Petrou S. Should health gains by children be given the same value as health gains by adults in an economic evaluation framework? In: Economic Evaluation in Child Health. Ungar WJ (Ed.), Oxford University Press, Oxford, UK, 71–87 (2010).
- Prosser LA. Comparative effectiveness and child health. Pharmacoeconomics 30(8), 637–645 (2012).
- Velasco-Garrido M, Busse R. Health Technology Assessment: an Introduction to Objectives, Role of Evidence, and Structure in Europe. World Health Organization Regional Office for Europe, on behalf of the European Observatory on Health Systems and Policies, Copenhagen, Denmark (2005).
- Caplan A. Vaccination: facts alone do not policy make. Health Aff. 30(6), 1205–1208 (2011).
Websites
- NICE. Guide to the methods of technology appraisal, UK National Institute for Health and Clinical Excellence June 2008. www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/?domedia=1&mid=B52851A3-19B9-E0B5-D48284D172BD8459 (Accessed 27 November 2012)
- Centre for Reviews and Dissemination. University of York; York (2013). www.crd.york.ac.uk/crdweb
- NICE. Medicines and prescribing support from NICE (2013). www.nice.org.uk/mpc/evidencesummariesnewmedicines/home.jsp
- Canadian Agency for Drugs and Technologies in Health. About the Common Drug Review (2013). www.cadth.ca/en/products/cdr/cdr-overview